It is proposed that tumor indolence is an actively maintained condition of restrained malignant potential, sustained by a multilayer restraint architecture encompassing lineage and epigenetic barriers, epithelial cell competition, immune containment, stromal organization, and vascular and metabolic limitations.
Abstract
Cancer screening detects lesions that meet pathological criteria for malignancy yet may remain clinically silent for years or decades. This paradox exposes a fundamental gap in cancer biology, although the mechanisms driving aggressiveness are well studied, far less is understood about what prevents malignant potential. Here, we propose that tumor indolence is an actively maintained condition of restrained malignant potential, sustained by a multilayer restraint architecture encompassing lineage and epigenetic barriers, epithelial cell competition, immune containment, stromal organization, and vascular and metabolic limitations. Within this framework, progression results not from a single decisive alteration but from the progressive erosion or collapse of these overlapping restraints. Reframing indolence in this way distinguishes biologically restrained lesions from cancers merely detected early and shifts the clinical objective from identifying cancer alone to predicting when restraint will fail, enabling more rational surveillance, risk stratification, and timely intervention while reducing overdiagnosis and overtreatment.
Cancer incidence has risen sharply over the past century. Despite enormous investments in cancer research and treatment, cancer continues to inflict immense human suffering and premature mortality. If current trends continue, nearly half of the populations in developed countries will develop cancer during their lifetim...
Jian Gao· International Journal of Env...· 0 citations
High-risk neuroblastoma remains a leading cause of pediatric cancer mortality, and relapse—driven by chemotherapy-resistant "persister" tumor cells that survive induction therapy—accounts for the majority of these deaths. Our recent single-nucleus and whole-genome sequencing analysis of matched diagnosis and definiti...
The present review explores the complex epigenetic mechanisms such as DNA methylation, histone modification and RNA editing that drive GBM progression, shape the tumor microenvironment and facilitate immune evasion and highlights the therapeutic potential of targeting these epigenetic vulnerabilities through inhibitors...
Immunotherapy has reshaped the treatment landscape of colorectal cancer (CRC), with the clearest and most durable benefit established in mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) disease. However, framing CRC immunotherapy simply as "MSI-H responsive versus microsatellite stable (MSS) res...
Cellular heterogeneity in pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for disease prognosis and limits the effectiveness of therapeutic strategies implemented in recent multicenter subtype-based clinical trials worldwide. A hallmark of PDAC is extensive intratumoral heterogeneity, which is la...
Xue-Yan Wu, L. Klein, M. Tu et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with one of the lowest five-year survival rates of all cancers. Low grade, premalignant pancreatic intraepithelial neoplasias (PanINs) are common in the general population, but despite expression of mutant KRAS, the vast majority of these lesions will n...
T. Gazdik, Madeline R. Kuhn, Kyra A. Lindley et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.